All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the AML Hub Steering Committee meeting, held on November 15, 2023, key opinion leaders met to discuss which patients should be considered for allogenic hematopoietic stem cell transplantation. This discussion was chaired by Charles Craddock and featured Jefferey Lancet, Roland Walter, Jorge Sierra, Gail Roboz, and Gert Ossenkoppele.
Which patients should be considered for allo-HSCT?
Charles Craddock discussed the optimization of transplant outcomes and highlighted key data from several recent studies. The steering committee considered factors that may impact transplant outcomes and the need to optimize patient status before transplant. They also discussed treatment decisions in older/unfit patients and explored factors to consider when deciding whether to proceed to transplant or pursue ongoing maintenance therapy.
Post-remission therapy for patients not proceeding to HSCT
During the AML Hub Steering Committee meeting in November 2023, key opinion leaders met to discuss postremission therapy for patients not proceeding to HSCT.
Optimizing transplant outcomes in patients allografted for AML
During the AML Hub Steering Committee meeting held on May 17, 2023, Charles Craddock chaired a discussion on optimizing transplant outcomes in patients allografted for AML, with...
Subscribe to get the best content related to AML delivered to your inbox